PDC*line Pharma Unveils New Clinical Data at CIMT 2025 Poster Presentation

We are proud to have presented a poster at the 22nd Annual Meeting of the Association for Cancer Immunotherapy (CIMT), held from May 21–23, 2025, in Mainz, Germany.

Poster title: “Humoral response in lung cancer patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine in combination with or without anti-PD1”

The poster presents new findings from our completed Phase I/II clinical trial (NCT03970746) with PDC*lung01, an irradiated allogeneic plasmacytoid dendritic cell line loaded with 7 HLA-A02:01-restricted tumor peptides for the treatment of HLA-A02:01+ lung cancer patients.

Key highlights of the data presented:
- Anti-HLA antibodies were detected in a subset of patients, predominantly targeting HLA-B7, B44, DR103, and DR801.
- These antibodies were dose-dependent and peaked post-vaccination—but importantly, no adverse clinical effects were associated with their presence.
- PDC*line cells were resistant to complement-dependent cytotoxicity, thanks to high expression of membrane-bound complement regulatory proteins (CD46, CD55, CD59).
- Notably, anti-PD1 treatment did not alter the nature, functionality, or dynamics of the anti-HLA IgG response.

These findings support the safety and robustness of our allogeneic PDC*line-based cancer vaccine platform, even in combination with immune checkpoint inhibitors.

Poster is available: /Poster CIMT 2025

About CIMT:

The CIMT Annual Meeting is Europe's premier meeting focused on cancer immunotherapy research and development. The Association for Cancer Immunotherapy CIMT is a member-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer imunotherapies. Since 2003, the CIMT Annual Meeting has connected the global cancer immunotherapy community in the heart of Europe. 

As the Europe's largest science-driven, not-for-profit event, the CIMT Annual Meeting invites international participants for high-level scientific exchange, collaboration and discussion focused on cancer immunotherapy.

For more information on the Association for Cancer Immunotherapy, please go to www.cimt.eu‍